Ann Hynes
Stock Analyst at Mizuho
(4.45)
# 349
Out of 4,761 analysts
231
Total ratings
65.06%
Success rate
13.31%
Average return
Main Sectors:
Stocks Rated by Ann Hynes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Outperform | $177 → $178 | $172.14 | +3.40% | 13 | Feb 3, 2025 | |
| MD Pediatrix Medical Group | Maintains: Neutral | $13 → $15 | $17.23 | -12.94% | 11 | Nov 19, 2024 | |
| ELV Elevance Health | Maintains: Outperform | $585 → $505 | $390.50 | +29.32% | 3 | Nov 5, 2024 | |
| CAH Cardinal Health | Maintains: Neutral | $110 → $120 | $127.38 | -5.79% | 8 | Nov 4, 2024 | |
| BTSG BrightSpring Health Services | Maintains: Outperform | $17 → $20 | $20.40 | -1.96% | 1 | Nov 4, 2024 | |
| CVS CVS Health | Maintains: Outperform | $73 → $66 | $65.09 | +1.40% | 9 | Oct 24, 2024 | |
| CON Concentra Group Holdings Parent | Initiates: Outperform | $28 | $23.41 | +19.61% | 1 | Aug 19, 2024 | |
| ARDT Ardent Health Partners | Initiates: Outperform | $20 | $14.84 | +34.77% | 1 | Aug 12, 2024 | |
| CRL Charles River Laboratories International | Initiates: Neutral | $235 | $162.25 | +44.84% | 1 | Jun 7, 2024 | |
| FTRE Fortrea Holdings | Initiates: Neutral | $27 | $15.61 | +72.97% | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $435 | $344.85 | +26.14% | 1 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $84 → $70 | $40.67 | +72.12% | 9 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 → $130 | $137.24 | -5.28% | 14 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $93 → $95 | $99.89 | -4.90% | 8 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $346 | $201.84 | +71.42% | 13 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $385 | $299.68 | +28.47% | 10 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $175 → $200 | $184.17 | +8.60% | 15 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $242 → $268 | $2.18 | +12,193.58% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $450 → $505 | $603.51 | -16.32% | 19 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $400 | $271.30 | +47.44% | 7 | Jan 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $257 → $230 | $249.17 | -7.69% | 15 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $275 | $321.50 | -14.46% | 20 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $31 → $25 | $10.51 | +137.87% | 8 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 → $229 | $194.01 | +18.04% | 10 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $50 | $25.67 | +94.78% | 2 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $549 | $502.42 | +9.27% | 16 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $76 | $58.48 | +29.96% | 7 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $345 → $366 | $291.46 | +25.57% | 6 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $57 | $1.64 | +3,372.22% | 1 | Sep 21, 2017 |
Quest Diagnostics
Feb 3, 2025
Maintains: Outperform
Price Target: $177 → $178
Current: $172.14
Upside: +3.40%
Pediatrix Medical Group
Nov 19, 2024
Maintains: Neutral
Price Target: $13 → $15
Current: $17.23
Upside: -12.94%
Elevance Health
Nov 5, 2024
Maintains: Outperform
Price Target: $585 → $505
Current: $390.50
Upside: +29.32%
Cardinal Health
Nov 4, 2024
Maintains: Neutral
Price Target: $110 → $120
Current: $127.38
Upside: -5.79%
BrightSpring Health Services
Nov 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $20.40
Upside: -1.96%
CVS Health
Oct 24, 2024
Maintains: Outperform
Price Target: $73 → $66
Current: $65.09
Upside: +1.40%
Concentra Group Holdings Parent
Aug 19, 2024
Initiates: Outperform
Price Target: $28
Current: $23.41
Upside: +19.61%
Ardent Health Partners
Aug 12, 2024
Initiates: Outperform
Price Target: $20
Current: $14.84
Upside: +34.77%
Charles River Laboratories International
Jun 7, 2024
Initiates: Neutral
Price Target: $235
Current: $162.25
Upside: +44.84%
Fortrea Holdings
May 28, 2024
Initiates: Neutral
Price Target: $27
Current: $15.61
Upside: +72.97%
May 28, 2024
Initiates: Buy
Price Target: $435
Current: $344.85
Upside: +26.14%
May 3, 2024
Maintains: Neutral
Price Target: $84 → $70
Current: $40.67
Upside: +72.12%
May 1, 2024
Reiterates: Buy
Price Target: $118 → $130
Current: $137.24
Upside: -5.28%
Apr 25, 2024
Maintains: Buy
Price Target: $93 → $95
Current: $99.89
Upside: -4.90%
Apr 4, 2024
Reiterates: Buy
Price Target: $346
Current: $201.84
Upside: +71.42%
Mar 8, 2024
Maintains: Buy
Price Target: $370 → $385
Current: $299.68
Upside: +28.47%
Mar 6, 2024
Maintains: Buy
Price Target: $175 → $200
Current: $184.17
Upside: +8.60%
Feb 23, 2024
Maintains: Buy
Price Target: $242 → $268
Current: $2.18
Upside: +12,193.58%
Feb 9, 2024
Maintains: Neutral
Price Target: $450 → $505
Current: $603.51
Upside: -16.32%
Jan 26, 2024
Maintains: Buy
Price Target: $550 → $400
Current: $271.30
Upside: +47.44%
Oct 31, 2023
Maintains: Buy
Price Target: $257 → $230
Current: $249.17
Upside: -7.69%
Oct 25, 2023
Maintains: Buy
Price Target: $325 → $275
Current: $321.50
Upside: -14.46%
Oct 10, 2023
Maintains: Neutral
Price Target: $31 → $25
Current: $10.51
Upside: +137.87%
Oct 10, 2023
Maintains: Buy
Price Target: $250 → $229
Current: $194.01
Upside: +18.04%
Jul 11, 2023
Maintains: Buy
Price Target: $48 → $50
Current: $25.67
Upside: +94.78%
Jul 11, 2023
Maintains: Buy
Price Target: $600 → $549
Current: $502.42
Upside: +9.27%
Jul 11, 2023
Maintains: Neutral
Price Target: $80 → $76
Current: $58.48
Upside: +29.96%
Jul 29, 2022
Maintains: Buy
Price Target: $345 → $366
Current: $291.46
Upside: +25.57%
Sep 21, 2017
Initiates: Neutral
Price Target: $57
Current: $1.64
Upside: +3,372.22%